References:
1. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular
system. Nature Reviews Cardiology. 2020;17(5):259-60.
2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T,
Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and
is blocked by a clinically proven protease inhibitor. Cell. 2020.
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and
risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. The lancet. 2020.
4. Kreutz R, Algharably EAE-H, Azizi M, Dobrowolski P, Guzik T,
Januszewicz A, et al. Hypertension, the renin–angiotensin system, and
the risk of lower respiratory tract infections and lung injury:
implications for COVID-19European Society of Hypertension COVID-19 Task
Force Review of Evidence. Cardiovascular Research. 2020.
5. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai
G, et al. Cardiovascular considerations for patients, health care
workers, and health systems during the COVID-19 pandemic. Journal of the
American College of Cardiology. 2020;75(18):2352-71.
6. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors
of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2:
a prospective cohort study. European Respiratory Journal. 2020;55(5).
7. World Health Organization. COVID-19 and the use of
angiotensin-converting enzyme inhibitors and receptor blockers:
scientific brief, 7 May 2020. World Health Organization; 2020.
8. Gilstrap LG, Fonarow GC, Desai AS, Liang L, Matsouaka R, DeVore AD,
et al. Initiation, continuation, or withdrawal of angiotensin‐converting
enzyme inhibitors/angiotensin receptor blockers and outcomes in patients
hospitalized with heart failure with reduced ejection fraction. Journal
of the American Heart Association. 2017;6(2):e004675.
9. Sparks M, Hiremath S. The coronavirus conundrum: ACE2 and
hypertension edition. NephJC. 2020.
10. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA,
Solomon SD. Renin–angiotensin–aldosterone system inhibitors in
patients with Covid-19. New England Journal of Medicine.
2020;382(17):1653-9.
11. International Society of Hypertension. A statement from the
International Society of Hypertension on COVID-19 2020 [Available
from:
https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/.
12. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu
NA, et al. Chloroquine and hydroxychloroquine for the prevention or
treatment of novel coronavirus disease (COVID-19) in africa: caution for
inappropriate off-label use in healthcare settings. The American journal
of tropical medicine and hygiene. 2020;102:1184-8.
13. Haque M, Islam S, Iqbal S, Urmi UL, Kamal ZM, Shuvo SA, et al.
Availability and price changes of potential medicines and equipment for
the prevention and treatment of COVID-19 among pharmacy and drug stores
in Bangladesh; findings and implications. Bangladesh Journal of Medical
Science. 2020.
14. Horby P, Landray M. No clinical benefit from use of
hydroxychloroquine in hospitalised patients with COVID-19 2020
[Available from:
https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.
15. World Health Organization. WHO discontinues hydroxychloroquine and
lopinavir/ritonavir treatment arms for COVID-19 2020 [Available from:
https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19.
16. National Institute of Health. NIH halts clinical trial of
hydroxychloroquine 2020 [Available from:
https://www.nhlbi.nih.gov/news/2020/nih-halts-clinical-trial-hydroxychloroquine.
17. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin
system inhibitors improve the clinical outcomes of COVID-19 patients
with hypertension. Emerging microbes & infections. 2020;9(1):757-60.
18. Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M, et al. Anti-hypertensive
Angiotensin II receptor blockers associated to mitigation of disease
severity in elderly COVID-19 patients. medRxiv.
2020:2020.03.20.20039586.
19. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with
different severities: a multicenter study of clinical features. American
journal of respiratory and critical care medicine. 2020;201(11):1380-8.
20. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of
inpatient use of angiotensin converting enzyme inhibitors and
angiotensin II receptor blockers with mortality among patients with
hypertension hospitalized with COVID-19. Circulation research. 2020.
21. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G.
Renin–angiotensin–aldosterone system blockers and the risk of
Covid-19. New England Journal of Medicine. 2020.
22. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson
SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of
Covid-19. New England Journal of Medicine. 2020.
23. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T,
Davidson KW, et al. Presenting characteristics, comorbidities, and
outcomes among 5700 patients hospitalized with COVID-19 in the New York
City area. Jama. 2020.
24. Li J, Wang X, Chen J, Zhang H, Deng A. Association of
renin-angiotensin system inhibitors with severity or risk of death in
patients with hypertension hospitalized for coronavirus disease 2019
(COVID-19) infection in Wuhan, China. JAMA cardiology. 2020.
25. Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects of
angiotensin II receptor blockers and ACE (Angiotensin-Converting Enzyme)
inhibitors on virus infection, inflammatory status, and clinical
outcomes in patients with COVID-19 and hypertension: a single-center
retrospective study. Hypertension (Dallas, Tex: 1979). 2020;76(1):51-8.
26. Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H, et al. Hypertension in
patients hospitalized with COVID-19 in Wuhan, China: A single-center
retrospective observational study. medRxiv. 2020:2020.04.06.20054825.
27. Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, et al.
Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in
Patients with Covid-19. medRxiv. 2020:2020.04.24.20077388.
28. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular
implications of fatal outcomes of patients with coronavirus disease 2019
(COVID-19). JAMA Cardiology 2020;5(7):811-8.
29. Grover A, Oberoi M. A systematic review and meta-analysis to
evaluate the clinical outcomes in COVID-19 patients on angiotensin
converting enzyme inhibitors or angiotensin receptor blockers. medRxiv.
2020.
30. Mackey K, King VJ, Gurley S, Kiefer M, Liederbauer E, Vela K, et al.
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or
Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A
Living Systematic Review. Annals of Internal Medicine. 2020.
31. Innovation VH. Covidence systematic review software. Veritas Health
Innovation Melbourne, Australia; 2016.
32. Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing
reviewers’ to authors’ assessments. BMC medical research methodology.
2014;14(1):45.
33. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al.
Newcastle-Ottawa quality assessment form for cohort studies. pp.
E17–E18. 2014.
34. Almeida PH, Silva TB, de Assis Acurcio F, Júnior AAG, Araújo VE,
Diniz LM, et al. Quality of life of patients with type 1 diabetes
mellitus using insulin analog glargine compared with NPH insulin: a
systematic review and policy implications. The Patient-Patient-Centered
Outcomes Research. 2018;11(4):377-89.
35. Bland JM, Altman DG. The odds ratio. British Medical Journal.
2000;320(7247):1468.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. British Medical Journal.
2003;327(7414):557-60.
37. Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, et
al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not
associated with severe SARS- COVID19 infection in a multi-site UK acute
Hospital Trust. medRxiv. 2020:2020.04.07.20056788.
38. Benelli G, Buscarini E, Canetta C, La Piana G, Merli G,
Scartabellati A, et al. SARS-COV-2 comorbidity network and outcome in
hospitalized patients in Crema, Italy. medRxiv.
2020:2020.04.14.20053090.
39. Dauchet L, Lambert M, Gauthier V, Poissy J, Faure K, Facon A, et al.
ACE inhibitors, AT1 receptor blockers and COVID-19: clinical
epidemiology evidences for a continuation of treatments. The ACER-COVID
study. medRxiv. 2020:2020.04.28.20078071.
40. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M,
et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among
2,026,227 United States Veterans Aged 54-75 Years. medRxiv.
2020:2020.04.09.20059964.
41. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al.
Association of use of angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers with testing positive for coronavirus
disease 2019 (COVID-19). JAMA cardiology. 2020.
42. Bravi F, Flacco ME, Carradori T, Volta CA, Cosenza G, De Togni A, et
al. Predictors of severe or lethal COVID-19, including Angiotensin
Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers, in a
sample of infected Italian citizens. medRxiv. 2020:2020.05.21.20109082.
43. Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, et al. Association of
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor
Blockers with the Risk of Hospitalization and Death in Hypertensive
Patients with Coronavirus Disease-19. medRxiv. 2020:2020.05.17.20104943.
44. Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M,
Grilli R. Characteristics and outcomes of a cohort of SARS-CoV-2
patients in the Province of Reggio Emilia, Italy. medRxiv.
2020:2020.04.13.20063545.
45. Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, et al. Role of
Drugs Affecting the Renin-Angiotensin-Aldosterone System on
Susceptibility and Severity of COVID-19: A Large Case-Control Study from
Zheijang Province, China. medRxiv. 2020:2020.04.24.20077875.
46. Chodick G, Nutman A, Yiekutiel N, Shalev V. Angiotension-converting
enzyme inhibitors and angiotensin-receptor blockers are not associated
with increased risk of SARS-CoV-2 infection. Journal of Travel Medicine.
2020.
47. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tre G,
Belmans L, et al. The effects of ARBs, ACEIs and statins on clinical
outcomes of COVID-19 infection among nursing home residents. medRxiv.
2020:2020.05.11.20096347.
48. Feng Z, Li J, Yao S, Yu Q, Zhou W, Mao X, et al. The Use of Adjuvant
Therapy in Preventing Progression to Severe Pneumonia in Patients with
Coronavirus Disease 2019: A Multicenter Data Analysis. medRxiv.
2020:2020.04.08.20057539.
49. Khawaja AP, Warwick AN, Hysi PG, Kastner A, Dick A, Khaw PT, et al.
Associations with covid-19 hospitalisation amongst 406,793 adults: the
UK Biobank prospective cohort study. medRxiv. 2020:2020.05.06.20092957.
50. Raisi-Estabragh Z, McCracken C, Ardissino M, Bethell MS, Cooper J,
Cooper C, et al. NON-WHITE ETHNICITY, MALE SEX, AND HIGHER BODY MASS
INDEX, BUT NOT MEDICATIONS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ARE
ASSOCIATED WITH CORONAVIRUS DISEASE 2019 (COVID-19) HOSPITALISATION:
REVIEW OF THE FIRST 669 CASES FROM THE UK BIOBANK. medRxiv.
2020:2020.05.10.20096925.
51. Rhee SY, Lee J, Nam H, Kyoung D-S, Kim DJ. Effects of a DPP-4
inhibitor and RAS blockade on clinical outcomes of patients with
diabetes and COVID-19. medRxiv. 2020:2020.05.20.20108555.
52. Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with
COVID-19 infection taking ACEI/ARB. Current cardiology reports.
2020;22:1-4.
53. Danser AJ, Epstein M, Batlle D. Renin-angiotensin system blockers
and the COVID-19 pandemic: at present there is no evidence to abandon
renin-angiotensin system blockers. Hypertension. 2020;75(6):1382-5.
54. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be
harmful in the COVID-19 pandemic? Journal of hypertension.
2020;38(5):781-2.
55. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and
diabetes mellitus at increased risk for COVID-19 infection? The Lancet
Respiratory Medicine. 2020;8(4):e21.